New therapeutic agents in thrombosis and thrombolysis

Resource Information

The work New therapeutic agents in thrombosis and thrombolysis represents a distinct intellectual or artistic creation found in University of Liverpool. This resource is a combination of several types including: Work, Language Material, Books.

Label

New therapeutic agents in thrombosis and thrombolysis

Statement of responsibility

edited by Jane E. Freedman, Joseph Loscalzo

Contributor

• Loscalzo, Joseph.
• Freedman, Jane E.

Subject

• Thrombolytic Therapy
• Platelet Aggregation Inhibitors -- therapeutic use
• Thrombosis -- drug therapy
• Fibrinolytic Agents -- therapeutic use
• Hemostasis -- drug effects
• Thrombosis
• Thrombolytic therapy
• Fibrinolytic agents

Language

eng

Summary

An essential text for cardiologists, hematologists, and pharmacologists, this third edition is a resource on current agent development technology for treating cardiovascular and thromboembolic diseases. It covers advances in scientific discovery, the growing number of patients and indications for antithrombotics, and more.

Member of

• Fundamental and clinical cardiology, v. 65
• Online access with DDA: Askews (Medicine)

Cataloging source

DNLM/DLC

Dewey number

616.13506

Illustrations

illustrations

Index

index present

LC call number

RC694.3

LC item number

.N49 2009

Literary form

non fiction

Nature of contents

bibliography

Series statement

Fundamental and clinical cardiology

Series volume

65

Summary expansion

As the number of patients with thrombosis and thrombolysis increases, there is a critical need for clinicians to learn the latest scientific discoveries and treatment options. This timely Third Edition is a comprehensive text for cardiologists, hematologists, and pharmacologists in need of a resource on current agent development technology for treating cardiovascular and thromboembolic diseases. New to the Third Edition: a thorough examination of all the agents involved in treating thrombosis chapters on biomarkers, testing, and pharmacogenomics key topics, including new targets for antithrombotics, the development of novel classes of platelet inhibitors, new thrombolytic therapies, and evolving clinical uses of thrombolytics for ischemic stroke and venous thrombosis the hemostatic and thrombotic pathways